Результаты поиска

Toxicology and carcinogenesis study of styrene-acrylonitrile trimer in F344/N rats (perinatal and postnatal feed studies).

UNLABELLED: Styrene-acrylonitrile trimer (SAN Trimer) is a mixture of isomers formed by the condensation of two moles of acrylonitrile and one mole of styrene and has a molecular weight of 210. The mixture is composed of two structural forms: 4-cyano-1,2,3,4-tetrahydro-a-methyl-1-naphthaleneacetonitrile (THNA, CAS No. 57964-39-3) and 4-cyano-1,2,3,4-tetrahydro-1-naphthalenepropionitrile (THNP, CAS No. 57964-40-6). The THNA form consists of four stereoisomers. [Structure:see text]. The THNP form consists of two stereoisomers. [Structure:see text]. SAN Trimer is a by-product of the production of

Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes. CD123, the α-subunit of interleukin (IL)-3 receptor, is constantly overexpressed at the surface of tumoral cells. Tagraxofusp (or SL-401) is a recombinant cytotoxin which consists of human interleukin-3 fused to a truncated diphtheria toxin. It is currently the only novel therapy with a prospective evaluation of efficacy and safety in the treatment of BPDCN and is also the only one to achieve FDA approval. In this short review, the results of tagraxofusp are

Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry.

BACKGROUND: Bladder cancer (BC) is one of the most common cancers and many patients will experience long-term survival. Non-urothelial second primary cancers (SPC) relatively frequently occur in the population of BC survivors. METHODS: Czech National Cancer Registry was the principal data source for this study. The risk of development of non-urothelial SPC after BC was assessed by the standardized incidence ratio (SIR). The standardized mortality ratio (SMR) was utilized to determine the risk of death from SPC following BC. RESULTS: Of the total of 61,314 patients with BC, a cohort of 12,645

Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms.

Background: The occurrence of myeloproliferative neoplasms (MPNs) that evolve into each other is well-described, as is this occurrence of lymphoproliferative neoplasms (LPNs). However, less is known about rare MPN/LPN coexistence, and the aim of our study was to analyze charachteristics of these patients after long term follow-up. Methods: Fourteen patients with MPN/LPN coexistence were diagnosed and treated according to guidelines at a single university center across two decades. Results: The overall median age was 53 years (22-69). MPNs patients with subsequent LPNs had a shorter period of s

Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region.

BackgroundPatients with B-cell neoplasms in remission are monitored with regular physician visits at the hospital. The current standard follow-up procedure is not evidence-based or individualized to patient needs. To improve and individualize the follow-up, we investigated the feasibility of a shared care follow-up initiative, with alternating physician visits and nurse-led telephone consultations and assessments based on patient-reported outcome (PRO) data.MethodsPatients ≥18 years diagnosed with B-cell neoplasms were eligible for the study when they were in remission and stable without treat

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Is photobiomodulation an effective preventive strategy for oral mucositis in patients with hematologic diseases undergoing chemotherapy?: A systematic review of randomized controlled trials.

Purpose to conduct a systematic review to assess whether photobiomodulation is effective in preventing oral mucositis in patients with hematologic diseases undergoing chemotherapy. Methods: A systematic search was conducted in the Embase, Medline/PubMed, Cochrane, Scopus, Web of Science and LILACS databases. The strategy included selected randomized clinical trials that evaluated the prevention of oral mucositis, directly comparing the use of photobiomodulation for chemotherapy-induced oral mucositis in patients with hematologic diseases with alternative non-laser therapies. The risk of bias i

Совпадение в полном тексте источника
… Neoplasms” OR Haematological OR “Haematological Malignancies” OR Leukemia OR Lymphoma) AND (Mucositis OR “Oral Mucositis”) AND (“Laser Therapy” OR “Low-Level Light Therapy” OR LLLT OR Photobiomodulation OR “Photodynamic therapy”) | No filters applied LILACS | (“Hematologic Neoplasms” OR Haematological … Light Therapy” OR LLLT OR Photobiomodulation OR “Photodynamic therapy” AND Mucositis OR “Oral Mucositis” (Word variations have been searched) | No filters applied Supportive Care in Cancer | “Hematologic Neoplasms” OR Haematological OR “Haematological Malignancies” OR Leukemia OR Lymphoma AND “Laser …

Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.

Although all myeloid cells are considered to derive from hematopoietic stem cells, the cells in each myeloid lineage are heterogeneous populations, and their distribution and functions vary, depending on underlying physiologic and pathologic processes, age, sex, and genetic and epigenetic signatures. In general, myeloid cells can be separated into circulating and tissue-resident cells. Tissue-resident myeloid cells can further be divided into cells derived from circulating monocytes, circulating stem cells, or local tissue-restricted stem or progenitor cells. Depending on underlying diseases a

Prognostic utility of macrophage polarization (CD68/CD163 ratio) in Egyptian JAK2 positive myeloproliferative neoplasm patients: a single center study.

BackgroundMyeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders with variable clinical outcomes influenced by the bone marrow microenvironment. Tumor-associated macrophages (TAMs), particularly the M1 (CD68⁺) and M2 (CD163⁺) subtypes, play critical roles in inflammation, fibrosis, and immune modulation. This study evaluates CD68- and CD163-positive macrophage frequencies across MPN subtypes and their clinical/prognostic significance.MethodsIn this retrospective cohort study, 121 patients with histopathologically confirmed BCR::ABL1-negative, JAK2V617F-positive MPNs were assess

Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm.

Purpose of reviewMyeloproliferative neoplasm (MPN) burdens the lives of those affected. MPN patients endure significant impacts on their physical, psychological, and social well-being. While pharmacological interventions offer some disease and symptom control, they often have unfavorable side effects. This review explores the potential of Integrative Oncology (IO) therapies in managing MPNs and their associated symptoms.Recent findingsIO is dedicated to augmenting conventional treatments through integrating interventions targeting the mind, body, nutrition, supplements, and other supportive ca

Упражнения и питание в гематологических заболеваниях: свидетельства перевода и новые меры вмешательства.

Пациенты, страдающие гематологическими микроорганизмами, включая лейкемию, лимфому и миелому, живут дольше из - за прогресса в лечении. Тем не менее такое лечение часто приводит к токсичным последствиям, влияющим на качество жизни пациентов (QoL). Хотя мероприятия, связанные с образом жизни, такие, как упражнение и питание, приносят пользу, снижая риск заболевания раком и улучшая результаты лечения твердых опухолей, их применение в гематологических опухолей по-прежнему недостаточно изучено. В настоящем описательном обзоре рассматриваются текущие данные о роли физических упражнений и питания в

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.

Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPN) are neoplastic diseases of the hematopoietic stem cells in the bone marrow. MPN are characterized by chronic inflammation and immune dysregulation. Of interest, the potent immunostimulatory cytokine interferon-α has been used to treat MPN for decades. A deeper understanding of the anti-cancer immune response and of the different immune regulatory mechanisms in patients with MPN has paved the way for an increased perception of the potential of cancer immunotherapy in MPN. Therapeutic vaccination targeting the driver mut

Связанная с терапией острая миелоидная лейкемия после плазмы лейкемии: доклад по делу и литературный обзор.

С улучшением выживаемости в миеломе (ММ) связанная с терапией острая лейкемия миэлоида (t-AML) стала клинически значимой второй первичной халатностью (SPM). Мы сообщаем о случае превращения MM в T-AML после мультиагентной химиотерапии и анализируем литературу о связанных с терапией лейкемиях в MM. Мы сообщаем о случае пациента, у которого был диагностирован первичный лейкемия клеток плазмы (тип ИгГ-И, R-ISS стадия III), который достиг полной ремиссии после лечения с помощью даратумумаба, линалидомида и дексаметазона после получения режима лечения, основанного на протеатических ингибиторах. Пац

Acute organ failure and risk of admission to intensive medical care in cancer patients: a single center prospective cohort study.

ObjectiveTo ascertain the cumulative incidence of acute organ failure and intensive care unit admission in cancer patients.MethodsThis was a single-center prospective cohort study of adult cancer patients admitted for unscheduled inpatient care while on systemic cancer treatment.ResultsBetween August 2018 and February 2019, 10,392 patients were on systemic treatment, 358 had unscheduled inpatient care and were eligible for inclusion, and 285 were included. The mean age was 60.9 years, 50.9% were male, and 17.9% of patients had hematologic cancers. The cumulative risk of acute organ failure was

Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Therapeutic monoclonal antibodies (mAbs) such as antibody-drug conjugates, ligand-receptor antagonists, immune checkpoint inhibitors and bispecific T cell engagers have shown impressive efficacy in the treatment of multiple human cancers. Numerous therapeutic mAbs that have been developed for myeloid neoplasms, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), are currently investigated in clinical trials. Because AML and MDS originate from malignantly transformed hematopoietic stem/progenitor cells-the so-called leukemic stem cells (LSCs) that are highly resistant to

Prognostic impact of the controlling nutritional status score in patients with hematologic malignancies: A systematic review and meta-analysis.

BackgroundAn increasing number of studies have validated the prognostic significance of the controlling nutritional status (CONUT) score in patients with solid tumors. However, the extent of the correlation between the CONUT score and clinical outcomes of patients with hematologic malignancies is unclear.ObjectiveThis study aimed to investigate the prognostic role of the CONUT score in patients with hematologic malignancies.MethodsAll relevant articles published up to November 15, 2021, were identified by systematically searching PubMed, Embase, Web of Science, and Cochrane Library. Pooled haz

Совпадение в полном тексте источника
… neoplasms”, and “hematologic neoplasms”. … Because of the controversial results from different studies, we conducted a meta-analysis to investigate the prognostic value of CONUT score in patients with hematologic neoplasms. …

Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges.

Ureteral involvement by diffuse large B-cell lymphoma (DLBCL) is an extremely rare clinical entity that can mimic primary urothelial carcinoma and pose a significant diagnostic challenge. A 70-year-old female patient initially presented to a urologist with renal colic. The patient denied fever, night sweats, unintentional weight loss, or prior hematologic disorders, and no peripheral lymphadenopathy was detected on physical examination. Multislice computed tomography (MSCT) revealed a ureteral mass, followed by cystoscopy with ureteral stent placement. Due to the strong clinical and radiologic

Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in β-Thalassemia Patients.

Patients affected by transfusion-dependent β-thalassemia are prone to developing several clinical complications, mostly related to the iron overload. We report the case of a patient affected by transfusion-dependent β-thalassemia (TDT) developing acute promyelocytic leukemia (APL). In our case, the therapeutic management was significantly complicated not only by myocardial dysfunction, but also by the occurrence of the differentiation syndrome following all-trans retinoic acid (ATRA) administration. We carried out a careful revision of the current literature on the occurrence of hematological

Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic.

Background/aimThe COVID-19 pandemic is a unique challenge to the care of patients with hematological malignancies. We aim to provide supportive guidance to clinicians making individual patients decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited.ConclusionThis review also provides recommendations, which are convenient in evaluating indications for therapy, reducing therapy-associated immunosuppression, and reducing healthcare utilization in patients with specific hematological malignancies in the COVID-19 era. Specific decisio

Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.

Therapy-related acute myeloid leukemia (t-AML) often exhibits adverse (genetic) features. There is ongoing discussion on the impact of t-AML on long-term outcome in AML. Therefore, we retrospectively analyzed clinical and biological characteristics of 1133 AML patients (225 t-AML patients and 908 de novo AML patients) with a median follow-up of 81.8 months. T-AML patients showed more adverse genetic alterations, higher age and more comorbidities as compared to de novo AML. Median OS in intensively treated t-AML patients was 13.7 months as compared to 39.4 months in de novo AML (p < 0.001). Wit